Biomarkers of Alzheimer's disease in body fluids.
Various innovative diagnostic methods for Alzheimer's disease (AD) have been developed in view of the increasing prevalence and consequences of later-life dementia. Biomarkers in cerebrospinal fluid (CSF) and blood for AD are primarily based on the detection of components derived from amyloid plaques and neurofibrillary tangles (NFTs). Published reports on CSF and blood biomarkers in AD indicate that although biomarkers in body fluids may be utilized in the clinical diagnosis of AD, there are no specific markers that permit accurate and reliable diagnosis of early-stage AD or the monitoring of disease progression.
Zheng
YanPeng
Y
College of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing 100044, China.
He
JinSheng
J
Hong
Tao
T
D000368:Aged; D000544:Alzheimer Disease / Q000097:blood / Q000134:cerebrospinal fluid / Q000175:diagnosis*; D015415:Biomarkers / Q000134:cerebrospinal fluid / Q000378:metabolism*; D001826:Body Fluids / Q000378:metabolism*; D003704:Dementia / Q000134:cerebrospinal fluid; D018450:Disease Progression; D006801:Humans; D016874:Neurofibrillary Tangles
D015415:Biomarkers